Drug mechanisms to help in managing resistant hypertension in obesity

Current Hypertension Reports

Volumn 12, Issue 4, 2010, Pages 220-225

  Jansen, Pieter M ^a   Danser, Jan A H ^a   Spiering, Wilko ^b   Van Den Meiracker, Anton H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Aldosterone; Antihypertensive therapy; Hypertension; Mineralocorticoid receptor antagonism; Obesity; Renin angiotensin system; Sympathetic nervous system

Indexed keywords

ALDOSTERONE; ALISKIREN; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; CANDESARTAN; DIURETIC AGENT; FELODIPINE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; METOPROLOL; MINERALOCORTICOID RECEPTOR; RAMIPRIL; SIBUTRAMINE; SPIRONOLACTONE; TRANDOLAPRIL PLUS VERAPAMIL; VALSARTAN;

ALDOSTERONE BLOOD LEVEL; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; LIFESTYLE MODIFICATION; LOW DRUG DOSE; NONHUMAN; OBESITY; PATHOGENESIS; PERIPHERAL EDEMA; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION;

ALDOSTERONE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HUMANS; HYPERTENSION; LIFE STYLE; OBESITY; RECEPTORS, MINERALOCORTICOID; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SYMPATHETIC NERVOUS SYSTEM; TREATMENT FAILURE;

EID: 77956268842     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-010-0123-5     Document Type: Review

References (49)

1. J Jordan S Engeli J Redon, et al. 2007 European Society of Hypertension Working Group on Obesity: background, aims and perspectives J Hypertens 25 4 897 900 10.1097/HJH.0b013e328051b510 1:CAS:528:DC%2BD2sXislSrtrc%3D 17351387
2. CD Brown M Higgins KA Donato, et al. 2000 Body mass index and the prevalence of hypertension and dyslipidemia Obes Res 8 9 605 619 10.1038/oby.2000.79 1:STN:280:DC%2BD3M3jtlKhtw%3D%3D 11225709
3. AM Sharma 2004 Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension 44 1 12 19 10.1161/01.HYP. 0000132568.71409.a2 1:CAS:528:DC%2BD2cXltVSqt7c%3D 15173127
4. PE Peppard T Young M Palta J Skatrud 2000 Prospective study of the association between sleep-disordered breathing and hypertension N Engl J Med 342 19 1378 1384 10.1056/NEJM200005113421901 1:STN:280:DC%2BD3c3kvVyhuw%3D%3D 10805822
5. WC Cushman CE Ford JA Cutler, et al. 2002 Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) J Clin Hypertens (Greenwich) 4 6 393 404 10.1111/j.1524-6175.2002.02045.x
6. DM Lloyd-Jones JC Evans MG Larson, et al. 2000 Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community Hypertension 36 4 594 599 1:STN:280: DC%2BD3cvpvFGnsQ%3D%3D 11040241
7. KP Davy JE Hall 2004 Obesity and hypertension: two epidemics or one? Am J Physiol Regul Integr Comp Physiol 286 5 R803 R813 1:CAS:528: DC%2BD2cXkt1entbk%3D 15068965
8. JE Hall 2003 The kidney, hypertension, and obesity Hypertension 41 3 Pt 2 625 633 10.1161/01.HYP.0000052314.95497.78 12623970
9. SP Bagby 2004 Obesity-initiated metabolic syndrome and the kidney: a recipe for chronic kidney disease? J Am Soc Nephrol 15 11 2775 2791 10.1097/01.ASN.0000141965.28037.EE 15504931
10. RB de Paula AA da Silva JE Hall 2004 Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration Hypertension 43 1 41 47 10.1161/01.HYP.0000105624.68174.00 14638627
11. S Kassab T Kato FC Wilkins, et al. 1995 Renal denervation attenuates the sodium retention and hypertension associated with obesity Hypertension 25 4 Pt 2 893 897 1:CAS:528:DyaK2MXlvVemt7Y%3D 7721450
12. MR Wofford DC Anderson Jr CA Brown, et al. 2001 Antihypertensive effect of alpha- and beta-adrenergic blockade in obese and lean hypertensive subjects Am J Hypertens 14 7 Pt 1 694 698 10.1016/S0895-7061(01)01293-6 1:CAS:528:DC%2BD3MXlvFajt7o%3D 11465655
13. DA Calhoun D Jones S Textor, et al. 2008 Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research Hypertension 51 6 1403 1419 10.1161/HYPERTENSIONAHA.108. 189141 1:CAS:528:DC%2BD1cXlvFaitLw%3D 18391085
14. I Hajjar TA Kotchen 2003 Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000 JAMA 290 2 199 206 10.1001/jama.290.2.199 12851274
15. MK Nishizaka M Pratt-Ubunama MA Zaman, et al. 2005 Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension Am J Hypertens 18 6 805 812 10.1016/j.amjhyper.2005.01. 002 1:CAS:528:DC%2BD2MXltVehtbw%3D 15925740
16. P Bramlage D Pittrow HU Wittchen, et al. 2004 Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled Am J Hypertens 17 10 904 910 10.1016/j.amjhyper.2004.05.017 15485752
17. PM Jansen F Boomsma AH van den Meiracker AI Dutch 2008 Aldosterone-to-renin ratio as a screening test for primary aldosteronism-the Dutch ARRAT Study Neth J Med 66 5 220 228 1:STN:280:DC%2BD1czislCgsw%3D%3D 18490805
18. PM Jansen AH Danser BP Imholz AH van den Meiracker 2009 Aldosterone-receptor antagonism in hypertension J Hypertens 27 4 680 691 10.1097/HJH.0b013e32832810ed 1:CAS:528:DC%2BD1MXjtlOltbw%3D 19516169
19. KK Gaddam MK Nishizaka MN Pratt-Ubunama, et al. 2008 Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion Arch Intern Med 168 11 1159 1164 10.1001/archinte.168.11.1159 1:CAS:528:DC%2BD1cXnvVSksrg%3D 18541823
20. E Ingelsson MJ Pencina GH Tofler, et al. 2007 Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study Circulation 116 9 984 992 10.1161/CIRCULATIONAHA.107.708537 1:CAS:528:DC%2BD2sXpt1GmtL0%3D 17698726
21. S Kidambi JM Kotchen CE Grim, et al. 2007 Association of adrenal steroids with hypertension and the metabolic syndrome in blacks Hypertension 49 3 704 711 10.1161/01.HYP.0000253258.36141.c7 1:CAS:528:DC%2BD2sXhslCmsbo%3D 17159085
22. C Dall'Asta P Vedani P Manunta, et al. 2009 Effect of weight loss through laparoscopic gastric banding on blood pressure, plasma renin activity and aldosterone levels in morbid obesity Nutr Metab Cardiovasc Dis 19 2 110 114 10.1016/j.numecd.2008.06.001 18718746
23. ML Tuck J Sowers L Dornfeld, et al. 1981 The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients N Engl J Med 304 16 930 933 1:CAS:528:DyaL3MXhslahu7g%3D 7010165
24. TL Goodfriend DA Calhoun 2004 Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy Hypertension 43 3 518 524 10.1161/01.HYP.0000116223.97436.e5 1:CAS:528:DC%2BD2cXhtlyntrs%3D 14732721
25. JR Sowers A Whaley-Connell M Epstein 2009 Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension Ann Intern Med 150 11 776 783 19487712 This is an excellent review about underlying mechanisms and potential links between aldosterone, insulin resistance, and hypertension
26. W Chai IM Garrelds R de Vries, et al. 2005 Nongenomic effects of aldosterone in the human heart: interaction with angiotensin II Hypertension 46 4 701 706 10.1161/01.HYP.0000182661.98259.4f 1:CAS:528:DC%2BD2MXhtV2htr%2FM 16144984
27. RC Frederich Jr BB Kahn MJ Peach JS Flier 1992 Tissue-specific nutritional regulation of angiotensinogen in adipose tissue Hypertension 19 4 339 344 1:CAS:528:DyaK38XktVKrur4%3D 1555865
28. F Massiera M Bloch-Faure D Ceiler, et al. 2001 Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation FASEB J 15 14 2727 2729 1:CAS:528:DC%2BD3MXptFags7k%3D 11606482
29. N Chapman J Dobson S Wilson, et al. 2007 Anglo-Scandinavian Cardiac Outcomes Trial I: effect of spironolactone on blood pressure in subjects with resistant hypertension Hypertension 49 4 839 845 10.1161/01.HYP.0000259805. 18468.8c 1:CAS:528:DC%2BD2sXivVamt78%3D 17309946
30. F de Souza E Muxfeldt R Fiszman G Salles 2010 Efficacy of spironolactone therapy in patients with true resistant hypertension Hypertension 55 1 147 152 10.1161/HYPERTENSIONAHA.109.140988 19858405 This study explores the effect and determinants of antihypertensive response in patients with true resistant hypertension. In this study, blood pressure was reduced by 16 and 9 mm Hg with add-on spironolactone therapy, and controlled ambulatory blood pressure was reached in 48% of patients. Independent factors associated with better response were higher waist circumference, lower aortic pulse wave velocity, and lower serum potassium concentration
31. DA Lane S Shah DG Beevers 2007 Low-dose spironolactone in the management of resistant hypertension: a surveillance study J Hypertens 25 4 891 894 10.1097/HJH.0b013e328014954d 1:CAS:528:DC%2BD2sXislSrtrg%3D 17351384
32. J Ouzan C Perault AM Lincoff, et al. 2002 The role of spironolactone in the treatment of patients with refractory hypertension Am J Hypertens 15 4 Pt 1 333 339 10.1016/S0895-7061(01)02342-1 1:CAS:528:DC%2BD38Xktlyktb8%3D 11991219
33. C Saha GJ Eckert WT Ambrosius, et al. 2005 Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension Hypertension 46 3 481 487 10.1161/01.HYP.0000179582.42830.1d 1:CAS:528:DC%2BD2MXptVWkurg%3D 16116042
34. Y Sharabi E Adler A Shamis, et al. 2006 Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension Am J Hypertens 19 7 750 755 10.1016/j.amjhyper.2005.11.016 1:CAS:528:DC%2BD28Xmt1Ort7o%3D 16814132
35. Reisin E, Weir MR, Falkner B, et al.: Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. Hypertension 1997, 30(1 Pt 1):140-145.
36. G Grassi G Seravalle R Dell'Oro, et al. 2003 Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study J Hypertens 21 9 1761 1769 10.1097/00004872-200309000-00027 1:CAS:528: DC%2BD3sXmtl2ksbo%3D 12923410
37. J Jordan S Engeli M Boschmann, et al. 2005 Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients J Hypertens 23 12 2313 2318 10.1097/01.hjh.0000188734.98463.82 1:CAS:528:DC%2BD2MXhtFOhsLfE 16269974
38. J Jordan S Engeli SW Boye, et al. 2007 Direct renin inhibition with aliskiren in obese patients with arterial hypertension Hypertension 49 5 1047 1055 10.1161/HYPERTENSIONAHA.106.084301 1:CAS:528:DC%2BD2sXktFagsLc%3D 17353513
39. WJ Elliott PM Meyer 2007 Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis Lancet 369 9557 201 207 10.1016/S0140-6736(07)60108-1 1:CAS:528:DC%2BD2sXntlCnsA%3D%3D 17240286
40. Cooper-DeHoff RM, Wen S, Beitelshees AL, et al.: Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. Hypertension, 55(1):61-68.
41. JE Neter BE Stam FJ Kok, et al. 2003 Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials Hypertension 42 5 878 884 10.1161/01.HYP.0000094221.86888.AE 1:CAS:528:DC%2BD3sXosFCmtrc%3D 12975389
42. E Pimenta KK Gaddam S Oparil, et al. 2009 Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial Hypertension 54 3 475 481 10.1161/HYPERTENSIONAHA.109. 131235 1:CAS:528:DC%2BD1MXpsleksbY%3D 19620517 This small but elegant study shows that excessive sodium intake can importantly contribute to resistance to antihypertensive treatment. The authors conclude that strategies that substantially reduce dietary salt intake should be part of the overall treatment of resistant hypertension
43. L Aucott A Poobalan WC Smith, et al. 2005 Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review Hypertension 45 6 1035 1041 10.1161/01.HYP.0000165680.59733.d4 1:CAS:528:DC%2BD2MXkt1OlsbY%3D 15897373
44. DW Haslam WP James 2005 Obesity Lancet 366 9492 1197 1209 10.1016/S0140-6736(05)67483-1 16198769
45. J Scholze E Grimm D Herrmann, et al. 2007 Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study Circulation 115 15 1991 1998 10.1161/CIRCULATIONAHA.106.625400 1:CAS:528:DC%2BD2sXjvFKjur4%3D 17404163
46. I Biaggioni 2008 Should we target the sympathetic nervous system in the treatment of obesity-associated hypertension? Hypertension 51 2 168 171 10.1161/HYPERTENSIONAHA.107.090514 1:CAS:528:DC%2BD1cXmt1OjtA%3D%3D 18086947
47. JM Mason HO Dickinson DJ Nicolson, et al. 2005 The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension J Hypertens 23 10 1777 1781 10.1097/01.hjh.0000177537.91527.09 1:CAS:528:DC%2BD2MXpslCmsb4%3D 16148594
48. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group 2002 The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 23 2981 2997 10.1001/jama.288.23.2981
49. CS Stump MT Hamilton JR Sowers 2006 Effect of antihypertensive agents on the development of type 2 diabetes mellitus Mayo Clin Proc 81 6 796 806 10.4065/81.6.796 1:CAS:528:DC%2BD28XmtVOmt7c%3D 16770980